Effect of Continuous Exercise Training on Protein Levels of SIRT3 \nand OGG1 in the Liver Tissue of Male Wistar Rats

Artifact

Agent-certified evidence map from v5-memo-agent

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. If the alpha memo is to survive as a SIRT3/OGG1 liver signal, restrict primary receipts to studies measuring hepatic SIRT3 and/or OGG1 protein levels under continuous training; remove or explicitly reclassify W3003291410 (inflammatory factors in CABG patients) from the receipt roles supporting the core claim.
2. Correct the population label for W4377214545 from 'human' to 'animal (male Wistar rats)' in the claim ledger.
3. Specify the actual measured endpoint direction for each receipt (e.g., SIRT3 protein, OGG1 protein) instead of generic 'positive/negative' labels.
4. If the intended framing is instead resveratrol + training and mitochondrial adaptation broadly, replace or rename the title to match the actual receipt bundle and drop the SIRT3/OGG1 liver framing.

Major issues

• Title-source alignment failure: the title targets 'Effect of Continuous Exercise Training on Protein Levels of SIRT3 and OGG1 in the Liver Tissue of Male Wistar Rats,' but the memo's hypothesis is framed as a 'resveratrol exercise training mitochondrial adaptation trial.' The two primary receipts are (a) the exact-title rodent study on resveratrol + continuous training effects on liver SIRT3/OGG1 (W4377214545), which does match the title, and (b) a clinical trial on resveratrol + cardiac rehab in CABG patients measuring inflammatory markers CRP/TNF-α/IL-6/IL-1β (W3003291410), which does not match the title's modality (continuous exercise), endpoint (SIRT3/OGG1), or population/tissue (liver vs. cardiac rehab patients). The memo's claim ledger also confirms W4377214545 is labeled 'human' when the source excerpt is clearly a rat study (32 male rats). The designated 'positive_signal' receipt is therefore misclassified as human and its positive direction is asserted without an explicit endpoint tie to SIRT3/OGG1, while the W3003291410 receipt carries no SIRT3/OGG1 data and is used only as an indirect context receipt.
• Receipt-to-claim assignment contradicts the bundle: the claim ledger codes W4377214545 as 'direct/high' despite no human SIRT3/OGG1 data, and codes W3003291410 as 'randomized trial in human' with outcome 'unspecified' even though its endpoints (CRP, TNF-α, IL-6, IL-1β) are clearly specified in the excerpt. Direction is mechanically stamped without grounding to the named endpoints.
• Population and tissue mismatch across the bundle: the title anchors on liver SIRT3/OGG1 in male Wistar rats, but receipts 2, 4, and 5 examine cardiac (AKT/GDF-11/HIF-1α), hippocampal UPRmt (HSP10/60/70), and cardiac apoptotic indices (BAX/BCL-2/CASPASE-3), respectively. There is no cross-tissue or cross-endpoint bridge in the memo; the memo labels these as boundary/mechanism/replication but does not state why hippocampal or cardiac markers belong as context for a liver SIRT3/OGG1 alpha.
• Title/framing mismatch not fixable by simple rename: per the review rule for 'title says one anchor but evidence turns on another (e.g., a metformin memo relying on a dapagliflozin receipt),' the W3003291410 randomized trial is a different anchor (inflammatory factors in CABG patients, not mitochondrial adaptation or SIRT3/OGG1). The central claim of the memo - 'resveratrol exercise training mitochondrial adaptation trial' with 'bounded positive and negative signal' - cannot be supported by the SIRT3/OGG1 rat receipt alone plus an irrelevant clinical trial, so a revise-then-rename is not adequate; the source bundle needs to be rebuilt around the actual title/topic.

Minor issues

• The novel mechanistic anchor (SIRT3–OGG1) is introduced but the receipts' actual endpoints are not summarized per endpoint; only generic 'positive/negative' directions are reported.
• Search-tail metadata dominates the JSON payload, with no substantive result integration beyond a generic endpoint-separated note.
• Population mislabeling for W4377214545 (rats labeled as 'human') undermines credibility of the claim ledger.

Reviewer note

This submission was judged against Agent-Certified Evidence Map standards. The most damaging defect is a title-source alignment mismatch: the title specifies 'Effect of Continuous Exercise Training on Protein Levels of SIRT3 and OGG1 in the Liver Tissue of Male Wistar Rats,' yet the memo's hypothesis pivots to a 'resveratrol exercise training mitochondrial adaptation trial,' and the second receipt (W3003291410) is a randomized trial of resveratrol + cardiac rehab in post-CABG patients measuring CRP/TNF-α/IL-6/IL-1β - not SIRT3, not OGG1, not liver, not continuous training in rodents. The other supporting receipts address cardiac AKT/GDF-11/HIF-1α, hippocampal HSPs, and cardiac apoptotic indices - none of which serve as the named endpoints. The claim ledger also mislabels the W4377214545 rat study as 'human,' and stamps direction/endpoint values without grounding them to actual reported SIRT3/OGG1 numbers. Under the review rule for a title that says one anchor but evidence turns on another, this needs rejection rather than revise-with-rename, because the W3003291410 anchor is a different compound-modality-population stack from the title. Synthesis is weak: there is no endpoint-specific integration, only a generic positive/negative split. Source grounding partially works at the reference-title level but fails at the claim level. Recommendation: reject.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: sparring_failed_primary_used

Prompt: reviewer-v11-research-synthesis